HC Wainwright Has Bullish Outlook for VRCA FY2028 Earnings
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Free Report) – Equities research analysts at HC Wainwright upped their FY2028 earnings per share estimates for Verrica Pharmaceuticals in a research note issued on Tuesday, April 8th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings per share of $0.11 for the year, up from […]
More Stories
Snowflake’s (SNOW) “Buy” Rating Reaffirmed at Rosenblatt Securities
Snowflake (NYSE:SNOW – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Rosenblatt Securities in...
Snap-on’s (SNA) Outperform Rating Reiterated at Barrington Research
Snap-on (NYSE:SNA – Get Free Report)‘s stock had its “outperform” rating reiterated by equities research analysts at Barrington Research in...
Charter Communications (NASDAQ:CHTR) Upgraded by Loop Capital to Buy Rating
Charter Communications (NASDAQ:CHTR – Get Free Report) was upgraded by research analysts at Loop Capital from a “hold” rating to...
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $11.00 at HC Wainwright
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price objective lowered by HC Wainwright from $12.00 to $11.00 in...
UBS Group Upgrades Delta Air Lines (NYSE:DAL) to Buy
Delta Air Lines (NYSE:DAL – Get Free Report) was upgraded by analysts at UBS Group from a “neutral” rating to...
Patterson-UTI Energy’s (PTEN) Neutral Rating Reaffirmed at Citigroup
Patterson-UTI Energy (NASDAQ:PTEN – Get Free Report)‘s stock had its “neutral” rating reiterated by stock analysts at Citigroup in a...